Skip to content

Research of the early warning and optimized intervention regime in patients vulnerable to coronary heart disease (CHD)

Research of molecular markers and serum proteomics after invented by Huoxue Jiedu TCM in in patients vulnerable to coronary heart disease (CHD)

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-PRNRC-07000012
Enrollment
Unknown
Registered
2007-11-20
Start date
2007-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease (CHD)

Interventions

Acute cardiovascular events group:nuture status
without acute cardiovascular event group:nuture status

Sponsors

China-Japan Friendship Hospital, The Ministry of Health of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Correspond to WHO diagnostic criteria on CHD; 2. Have had history of myocardial infarct in the past or have been confirmed by coronary artery angiography that stenosis=50% in at least one coronary artery; 3. Clinical presentation includes asymptom, stable angina pectoris of effort, other types of angina pectoris; or ACS patients of disease course>1 mon and of stable condition; 4. Age =75 years old.

Exclusion criteria

Exclusion criteria: 1. Have history of infection, fever, trauma, empyrosis and surgery in latest one month; 2. Patients with active tuberculosis or disease of rheumatism and immunity; 3. Patients with severe heart failure, EF2.5mg/dl(221µmol/L) in males and >2.0mg/dl(177umol/L) in female; 7. Confirmed hepatic disfunction, measures of basic hepatic enzyme increase more than three times higher than normal range or combined with hepatic cirrhosis; 8. Severe disease of hematopoietic system; 9. Patients of severe mental disorder; 10. Patients of malignant tumor; 11. Patients with organs transplantation; 12. Patients with life expectancy shorter than 3 years.

Design outcomes

Primary

MeasureTime frame
acute cardiovascular events;

Secondary

MeasureTime frame
Biochemistry and physical outcomes;Liver and kidney function;

Countries

China

Contacts

Public ContactHao Xu
Xuhao2005@yahoo.com.cn+86 10 84205137

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 3, 2026